1.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
|
|
6.
|
Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
|
|
7.
|
Phase: Phase I Type: Treatment Status: Active Age: 3 to 22 Sponsor: Pharmaceutical / Industry Protocol IDs: 07-098, NCT00634231
|
|
8.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
|
|
10.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 163588-1, NCT01682746
|
|
11.
|
Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 2 to 25 Sponsor: Other Protocol IDs: 2005P001629, NCT01115777
|
|
12.
|
Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569
|